These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 39125707)

  • 41. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
    N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
    Joly BS; Darmon M; Dekimpe C; Dupont T; Dumas G; Yvin E; Beranger N; Vanhoorelbeke K; Azoulay E; Veyradier A
    J Thromb Haemost; 2021 Sep; 19(9):2193-2198. PubMed ID: 34219357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).
    Gerritsen HE; Turecek PL; Schwarz HP; Lämmle B; Furlan M
    Thromb Haemost; 1999 Nov; 82(5):1386-9. PubMed ID: 10595623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis.
    Masias C; Cataland SR
    Blood; 2018 Aug; 132(9):903-910. PubMed ID: 30006329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical features and laboratory findings of thrombotic thrombocytopenic purpura associated with ticlopidine].
    Yagi H
    Rinsho Byori; 2005 Jul; 53(7):630-8. PubMed ID: 16104532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathophysiology of thrombotic thrombocytopenic purpura.
    Tsai HM
    Int J Hematol; 2010 Jan; 91(1):1-19. PubMed ID: 20058209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.
    Moake JL
    Arch Pathol Lab Med; 2002 Nov; 126(11):1430-3. PubMed ID: 12421153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/ thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other?
    Shibagaki Y; Fujita T
    Hypertens Res; 2005 Jan; 28(1):89-95. PubMed ID: 15969259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
    Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
    Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Thrombotic thrombocytopenic purpura].
    Yoshitaka M
    Rinsho Ketsueki; 2021; 62(5):430-434. PubMed ID: 34108326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Research Advances of Acquired Thrombotic Thrombocytopenic Purpura--Review].
    Jia X; He Y; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1230-1234. PubMed ID: 30111436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
    Di Pasquale I; Budde U; Tona F; Bertomoro A; Lombardi AM; Famoso G; Bertozzi I; Dittmer R; Schneppenheim S; Fabris F
    Thromb Res; 2019 Jan; 173():42-47. PubMed ID: 30471507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
    Chen M; Shortt J
    Transfus Med Rev; 2022 Oct; 36(4):204-214. PubMed ID: 36396570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TTP and ADAMTS13: When Is Testing Appropriate?
    Mannucci PM; Peyvandi F
    Hematology Am Soc Hematol Educ Program; 2007; ():121-6. PubMed ID: 18024619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of n-acetylcysteine therapy in patients with relapsed refractory thrombotic thrombocytopenic purpura.
    Beyler O; Demir C
    Transfus Apher Sci; 2023 Aug; 62(4):103713. PubMed ID: 37137784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. von Willebrand factor and thrombotic thrombocytopenic purpura.
    Raife TJ; Montgomery RR
    Curr Opin Hematol; 2000 Sep; 7(5):278-83. PubMed ID: 10961577
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
    George JN
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):627-32. PubMed ID: 16167049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Thrombotic-thrombocytopenic purpura].
    Hellmann M; Hallek M; Scharrer I
    Internist (Berl); 2010 Sep; 51(9):1136, 1138-44. PubMed ID: 20689903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of ADAMTS13 and Von Willebrand factor levels and activities, and plasminogen levels, in plasma products currently available for the treatment of thrombotic thrombocytopenic purpura in South Africa.
    van Marle AC; Joubert J; Meiring SM
    Transfus Apher Sci; 2019 Feb; 58(1):72-78. PubMed ID: 30551950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.